Alivus Life Sciences Limited Fundamental Analysis (BSE: ALIVUS.BO)
Alivus Life Sciences Limited Fundamental Analysis (BSE: ALIVUS.BO)
Alivus Life Sciences Limited (BSE: ALIVUS.BO) shows moderate financial fundamentals with a PE ratio of 51.34, profit margin of 24.27%, and ROE of 10.00%. The company generates $13.3B in annual revenue with moderate year-over-year growth of 7.59%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 52.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ALIVUS.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakALIVUS.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateALIVUS.BO shows balanced valuation metrics.
Growth Score
ExcellentALIVUS.BO delivers strong and consistent growth momentum.
Financial Health Score
ModerateALIVUS.BO shows balanced financial health with some risks.
Profitability Score
WeakALIVUS.BO struggles to sustain strong margins.
Key Financial Metrics
Is ALIVUS.BO Expensive or Cheap?
P/E Ratio
ALIVUS.BO trades at 51.34 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ALIVUS.BO's PEG of -3.44 indicates potential undervaluation.
Price to Book
The market values Alivus Life Sciences Limited at 4.97 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 35.11 times EBITDA. This signals the market has high growth expectations.
How Well Does ALIVUS.BO Make Money?
Net Profit Margin
For every $100 in sales, Alivus Life Sciences Limited keeps $24.27 as profit after all expenses.
Operating Margin
Core operations generate 28.99 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.00 in profit for every $100 of shareholder equity.
ROA
Alivus Life Sciences Limited generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Alivus Life Sciences Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Alivus Life Sciences Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ALIVUS.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
51.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.44
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.97
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.45
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How ALIVUS.BO Stacks Against Its Sector Peers
| Metric | ALIVUS.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 51.34 | 30.97 | Worse (Expensive) |
| ROE | 10.00% | 515.00% | Weak |
| Net Margin | 24.27% | 30197.00% | Weak |
| Debt/Equity | 0.00 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 5.71 | Weak Liquidity |
| ROA | 0.00% | -16.00% (disorted) | Weak |
ALIVUS.BO outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alivus Life Sciences Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
7.41%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
16.05%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
37.39%
Industry Style: Defensive, Growth, Innovation
High Growth